• MR System

    Image Guided Thermal Therapy

    The BSD-2000 3D/MR employs the next generation of non-invasive thermometry.
    MR images are translated to map and visualize temperature, allowing
    for precision placement of the hyperthermic heating zone.
    Not for sale in the United States.
  • BSD-200 3D/MR Open Applicator

    Increase Workflow with
    easier patient access

    The Sigma Eye/MR applicator's side opening allows for more natural
    patient access. The unit can be removed and stored, allowing
    the MR system to be used for traditional imaging.
    Not for sale in the United States.
  • BSD-2000 3D/MR Dr with Patient

    Temperature Imaging during treatment

    There is no interruption during the hyperthermia/imaging process. The patient remains in the
    MR system during the full course of treatment. A water bolus is used to make connection
    between the RF signal and the patient. Circulated water can be cooled or heated for patient comfort.
    Not for sale in the United States.
  • BSD-2000 3D/MR Operator

    Realtime Heat Zone Steering

    A great benefit of image-guided thermal therapy
    is the ability to validate and electronically steer the heat zone to
    ensure proper treatment placement and target temperature.
    Not for sale in the United States.

Who is Pyrexar Medical

By leveraging the therapeutic power of focused heat, Pyrexar Medical seeks to revolutionize cancer care. We aim to enhance traditional cancer therapies, with clinically proven and effective options.

We are committed to continuing to advance these pioneering solutions, as we strive to redefine the landscape of cancer care for a brighter and healthier future.

Pyrexar Medical Quality Certifications

Clinical Evidence Matters

Randomized clinical trials (RCT’s) have show significant improvement in clinical outcomes when hyperthermia was added to radiotherapy and/or chemotherapy. Experts in clinical hyperthermia held a consensus meeting (Kadota Fund International Forum 2004) about the evidence of the published clinical results of the RCT’s. Level 1 evidence was found for bladder cancer, breast cancer, cervical cancer, cancer of the esophagus, lymph nodes of head and neck tumors, rectum cancer, soft tissue sarcoma, malignant melanoma, glioblastoma multiform, and various superficial cancers.

Hyperthermia chart demonstrating proven clinical results
Cancer Immune Modulaton

Heat Matters

According to the standards set by the Society of Thermal Medicine (STM), European Society for Hyperthermic Oncology (ESHO) and the Asian Society of Hyperthermic Oncology (ASHO), the benefits of hyperthermia are fully realized when the tumor temperature reaches 39-43 degrees Celsius.

Heat is known to kill cancer cells, shrink tumor size, increase radiosensitivity, inhibit DNA repair, oxygenate hypoxic tumors, produce heat shock proteins, and increase disease-free survival.

Clinical Study Reveals Increased Longevity

An independent study published in the Journal of the American Medical Association (JAMA) reports on a 10 year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study. In addition to higher CR, the addition of hyperthermia increased the median long-term survival rate from 6.2 to 15.4 years

Infographic of Soft Tissue Sarcoma Study

vaginal

  • Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: a cohort study

    Authors: Aktas M, de Jong D, Nuyttens JJ, van der Zee J, Wielheesen DH, Batman E, Burger CW, Ansink AC.
    Publication: Eur J Obstet Gynecol Reprod Biol. 2007 Jul;133(1):100-4. Epub 2006 Jun 13.

    OBJECTIVE:
    To evaluate the supplementary value of adding hyperthermia to radiotherapy in patients with primary vaginal cancer.

  • Concomitant RT and HT for primary carcinoma of the vagina

    Abstract: Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study

    Objective

    To evaluate the supplementary value of adding hyperthermia to radiotherapy in patients with primary vaginal cancer.

    Study design

    Cohort of 44 patients diagnosed with primary vaginal cancer between 1990 and 2002 was assessed. Survival rates and median survival of patients with primary vaginal cancer undergoing radiotherapy with and without hyperthermia were compared. Hyperthermia was solely added to radiotherapy in case of a tumor size >4 cm in diameter for FIGO stage III disease.

    Results

    The calculated overall 5-year survival of primary vaginal cancer was 63%. In comparison to histologic high grade tumors, higher survival rates for histologic low grade tumors were calculated. For FIGO stage III of disease, the addition of hyperthermia to radiotherapy for tumors >4 cm in diameter resulted similar survival rates and median survival when compared to those achieved by radiotherapy as monotherapy in tumors of <4 cm in diameter.

    Conclusions

    The addition of hyperthermia to radiotherapy might result in better survival rates in primary vaginal cancer for tumors >4 cm in diameter. The supplementary effect of hyperthermia to radiotherapy may be a feasible and beneficial approach in the treatment of vaginal cancer.

    Authors

    Aktas M, de Jong D, Nuyttens JJ, van der Zee J, Wielheesen DHM, Batman E, Burger CW, Ansink AC.

    Study Link

    Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study.
    European Journal of Obstetrics & Gynecology and Reproductive Biology 2007;133(1):100-4.

    {module=348}

Benefits of Hyperthermia in Cancer Treatment*

Effects Tumor Cell

In the delicate micro-environment of a cancer cell, heat can lead to direct cell death, shrinking tumor size for easier surgical resection.

Low Toxicity

Very low to no toxicity is often reported when administering hyperthermia. There is no known toxicity build-up from multiple treatments.

Increase Blood Flow

Increased blood flow and perfusion at the tumor site promote oxygenation, increasing radiosensitivity.

Survival Benefit

A phase III clinical study shows an increased survival benefit when hyperthermia was added to traditional therapies.

Inhibits DNA Repair

Hyperthermia, in combination with Radiotherapy, will inhibit the DNA repair cycle of radiation-damaged cancer cells.

Heat Shock Proteins

Tumor cells express heat shock proteins when exposed to hyperthermic temperatures allowing tumor-specific antigens to reach the immune system.

Our Products

 

To serve you better, this website has two viewing options.

Please make a selection before entering this site:

I am looking for products
Within the United States or Outside the United States

 
This website has restricted marketing content for visitors within the United States.